A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer
Latest Information Update: 24 Aug 2022
At a glance
- Drugs Darolutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacokinetics
- Acronyms ARAFOR
- Sponsors Orion; Orion Pharma
- 04 Jul 2022 Results of pooled analysis from NCT02363855, NCT01317641/NCT01429064, and NCT01784757, evaluating safety and tolerability of long-term treatment with darolutamide in patients, presented at the 37th Congress of the European Association of Urology
- 16 May 2022 Results presented at the 117th Annual Meeting of the American Urological Association
- 19 Feb 2022 Results of pooled analysis assessing long term safety by using data from three phase I/II studies presented at the 2022 Genitourinary Cancers Symposium